Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2011, Article ID 128295, 5 pages
http://dx.doi.org/10.1155/2011/128295
Review Article

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy

Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, P.O. Box 208063, New Haven, CT 06520-8063, USA

Received 30 May 2011; Revised 27 June 2011; Accepted 27 June 2011

Academic Editor: Bradley J. Monk

Copyright © 2011 Karim S. ElSahwi and Alessandro D. Santin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [7 citations]

The following is the list of published articles that have cited the current article.

  • Duangmani Thanapprapasr, Chalong Cheewakriangkrai, Puchong Likittanasombut, Kamolrat Thanapprapasr, and David G Mutch, “Targeted endometrial cancer therapy as a future prospect,” Women's Health, vol. 9, no. 2, pp. 189–199, 2013. View at Publisher · View at Google Scholar
  • Sayid Shafi Zuhur, Canan Tanik, Rumeysa Selvinaz Erol, Ahmet Murat Musluman, Fevziye Kabukcuoglu, and Yuksel Altuntas, “Immunohistochemical Expression of ErbB2 in Adamantinomatous Craniopharyngiomas: A Possible Target for Immunotherapy,” Turkish Neurosurgery, vol. 23, no. 1, pp. 55–60, 2013. View at Publisher · View at Google Scholar
  • Georgios Androutsopoulos, Georgios Michail, Georgios Adonakis, and Georgios Decavalas, “ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer,” Journal of Cancer Therapy, vol. 05, no. 06, pp. 483–492, 2014. View at Publisher · View at Google Scholar
  • Youn Jee Chung, Hyun Jung Kim, Sang Ho Park, Joo Hee Yoon, Mee Ran Kim, Suk Woo Nam, David T. MacLaughlin, Patricia K. Donahoe, and Jang Heub Kim, “Transcriptome analysis reveals that Mullerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis,” International Journal Of Oncology, vol. 46, no. 5, pp. 2039–2046, 2015. View at Publisher · View at Google Scholar
  • Muhieddine Seoud, Elisabeth Åvall Lundqvist, and Keiichi Fujiwara, “Targeted therapy in gynecologic cancers: Ready for prime time?,” International Journal of Gynecology & Obstetrics, vol. 131, pp. S150–S152, 2015. View at Publisher · View at Google Scholar
  • Weihua Yuan, Jie Chen, Ying Cao, Lingcong Yang, Luxi Shen, Qi Bian, Shufang Bin, Panyuan Li, Jiawei Cao, Hezhi Fang, Haihua Gu, and Hongzhi Li, “Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene,” The Journal of Gene Medicine, pp. e3027, 2018. View at Publisher · View at Google Scholar
  • Se Ik Kim, Ji Won Lee, Nara Lee, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, and Jeong-Sun Seo, “LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data,” BMC Cancer, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar